Table 1 Characterization of patients
SORTED ALVEOLAR MACROPHAGES | TOTAL BAL CELLS | |||
|---|---|---|---|---|
All sarcoidosis patients (n = 22) | Löfgren's syndrome (n = 11) | Non-Löfgren's syndrome (n = 11) | All sarcoidosis patients (n = 14) | |
Sex, male/female | 9/13 | 3/8 | 6/5 | 9/5 |
Age, yr | 38 (32-47)** | 38 (32-39)# | 40 (31-55)## | 40 (34-67)φ |
Smoker (yes/ex/never) | 1/7/14 | 0/3/8 | 1/4/6 | 1/4/8 (1 nd) |
X-ray stage (0/I/II/III/IV) | 0/11/7/3/1 | 0/9/2/0/0 | 0/2/5/3/1 | 2/3/7/1/0 (2 nd) |
Oral steroid treatment | 0 | 0 | 0 | 0 |
BAL analyses | ||||
% Recovery | 73 (61-77) | 73 (63-76) | 72 (59-79) | 68 (59-71) |
% Viability | 94 (92-96) | 94 (92-98) | 94 (92-95) | 95 (92-97) |
Cell concentration (*106/L) | 197 (130-250)** | 173 (131-225)# | 213 (119-296)## | 203 (153-257) |
Total cell number (*106) | 30 (24-38)** | 31 (25-38)# | 27 (23-45)# | 32 (24-36) |
BAL differential cell counts | ||||
% Macrophages | 74 (62-79)* | 74 (62-79) | 73 (61-81) | 69 (52-76) |
% Lymphocytes | 24 (18-38)** | 23 (19-37)# | 26 (15-39) | 31 (22-47)φ |
% Neutrophils | 0.9 (0-6-2.5) | 1.0 (0.8-3.6) | 0.8 (0.5-2.0) | 1.0 (0.6-2.0) |
% Eosinophils | 0.3 (0-1.1) | 0.2 (0-1.0) | 0.5 (0-1.6) | 0.4 (0-1.3) |
CD4/CD8 ratio | 7.9 (3.6-16) | 8.5 (4.7-12) | 6.7 (2.0-19) | 8.5 (2.4-15) |
Pulmonary function tests | ||||
VC | 89 (81-97) | 89 (81-96) | 87 (75-98) | 87 (79-100) |
FEV1 | 88 (84-99) | 87 (85-100) | 94 (82-99) | 85 (79-96) |
DLCO | 86 (73-94) | 86 (73-95) | 84 (73-93) | 85 (75-99) |